))
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Manage episode 401326661 series 2838329
Inhoud geleverd door VJHemOnc. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door VJHemOnc of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents.
In this podcast, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Aaron Goldberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, comment on the growing role of targeted agents in AML. The experts draw focus on the promise of menin inhibitors, highlighting findings from the AUGMENT-101 (NCT04065399) and KOMET-008 (NCT05735184) trials.
200 afleveringen
Delen
